Determination of ED 50 and ED 95 of remimazolam besylate combined with alfentanil for adult gastroscopy: a prospective dose-finding study.

Background: To explore the median effective dose (ED50) and 95% effective dose (ED95) of remimazolam besylate combined with alfentanil for adult gastroscopy.
Methods: This prospective studyenrolled 31 patients scheduled to painless gastroscopy at Anhui No. 2 Provincial People's Hospital between April and May, 2022. 5 µg.kg ^-1 of alfentanil hydrochloride was used for pre-analgesia. The initial single loading dose of remimazolam besylate was 0.12 mg.kg ^-1 , increased or reduced by 0.01 mg.kg ^-1 for the next patient with modified Dixon sequential method. The modified Observer's Assessment of Alertness/Sedation Scale (MOAA/S) was used to assess sedation.
Results: Combined with alfentanil, the ED50 of remimazolam besylate was 0.147 mg.kg ^-1 (95% CI: 0.138-0.160 mg.kg ^-1 ) and ED95 0.171 mg.kg ^-1 (95% CI: 0.159-0.245 mg.kg ^-1 ). The induction time after injection of remimazolam besylate was 70 ± 25 s, with the anesthesia recovery time and the observation time in resuscitation room 5.13 ± 2.13 min and 2.32 ± 1.6 min, respectively. Twenty nine patients' vital signs were within acceptable limits during gastroscopy.
Conclusions: The ED50 of remimazolam besylate combined with alfentanil for painless gastroscopy was 0.147 mg.kg ^-1 , and the ED95 was 0.171 mg.kg ^-1 .
Competing Interests: Declaration of competing interest The authors declare no conflicts of interest.
(Copyright © 2024. Published by Elsevier España S.L.U.)